The emerging postural instability phenotype in idiopathic Parkinson disease.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
18 Mar 2022
18 Mar 2022
Historique:
received:
22
08
2020
accepted:
01
02
2022
entrez:
19
3
2022
pubmed:
20
3
2022
medline:
20
3
2022
Statut:
epublish
Résumé
Identification of individuals at high risk for rapid progression of motor and cognitive signs in Parkinson disease (PD) is clinically significant. Postural instability and gait dysfunction (PIGD) are associated with greater motor and cognitive deterioration. We examined the relationship between baseline clinical factors and the development of postural instability using 5-year longitudinal de-novo idiopathic data (n = 301) from the Parkinson's Progressive Markers Initiative (PPMI). Logistic regression analysis revealed baseline features associated with future postural instability, and we designated this cohort the emerging postural instability (ePI) phenotype. We evaluated the resulting ePI phenotype rating scale validity in two held-out populations which showed a significantly higher risk of postural instability. Emerging PI phenotype was identified before onset of postural instability in 289 of 301 paired comparisons, with a median progression time of 972 days. Baseline cognitive performance was similar but declined more rapidly in ePI phenotype. We provide an ePI phenotype rating scale (ePIRS) for evaluation of individual risk at baseline for progression to postural instability.
Identifiants
pubmed: 35304493
doi: 10.1038/s41531-022-00287-x
pii: 10.1038/s41531-022-00287-x
pmc: PMC8933561
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Subventions
Organisme : NINDS NIH HHS
ID : K23 NS083620
Pays : United States
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : K23NS083620
Informations de copyright
© 2022. The Author(s).
Références
Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression, and mortality. 1967. Neurology 57, S11 (2001).
pubmed: 11775596
Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov. Disord. 19, 1020–1028 (2004).
pubmed: 15372591
doi: 10.1002/mds.20213
Jankovic, J. et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. Neurology 40, 1529 (1990).
pubmed: 2215943
doi: 10.1212/WNL.40.10.1529
Stebbins, G. T. et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov. Disord. 28, 668–670 (2013).
pubmed: 23408503
doi: 10.1002/mds.25383
Simuni, T. et al. How stable are Parkinson’s disease subtypes in de novo patients: analysis of the PPMI cohort? Parkinsonism Relat. Disord. 28, 62–67 (2016).
pubmed: 27132498
doi: 10.1016/j.parkreldis.2016.04.027
Fahn, S., Elton, R. & UPDRS program members. Unified Parkinsons Disease Rating Scale. In Recent Developments in Parkinsons Disease, Vol. 2 (eds. Fahn, S., Marsden, C., Goldstein, M. & Calne, D.) 153–163 (Macmillan Healthcare Information, 1987).
Goetz, C. G. et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).
pubmed: 19025984
doi: 10.1002/mds.22340
Huang, X. et al. Non‐motor symptoms in early Parkinson’s disease with different motor subtypes and their associations with quality of life. Eur. J. Neurol. 26, 400–406 (2019).
pubmed: 30175887
doi: 10.1111/ene.13803
Wu, Y. et al. Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson’s disease patients. Acta Neurol. Scand. 133, 330 (2016).
pubmed: 26195131
doi: 10.1111/ane.12461
Post, B., Merkus, M. P., de Haan, R. J. & Speelman, J. D. Prognostic factors for the progression of Parkinson’s disease: a systematic review. Mov. Disord. 22, 1839–1851 (2007).
pubmed: 17595026
doi: 10.1002/mds.21537
Pal, G. et al. Global cognitive function and processing speed are associated with gait and balance dysfunction in Parkinson’s disease. J. Neuroeng. Rehabil. 13, 94 (2016).
pubmed: 27793167
pmcid: 5084375
doi: 10.1186/s12984-016-0205-y
Alves, G., Larsen, J. P., Emre, M., Wentzel‐Larsen, T. & Aarsland, D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov. Disord. 21, 1123–1130 (2006).
pubmed: 16637023
doi: 10.1002/mds.20897
Zuo, L.-J. et al. Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters. Sci. Rep. 7, 44872 (2017).
pubmed: 28332604
pmcid: 5362957
doi: 10.1038/srep44872
Kelly, V. E. et al. Association of cognitive domains with postural instability/gait disturbance in Parkinson’s disease. Parkinsonism Relat. Disord. 21, 692–697 (2015).
pubmed: 25943529
pmcid: 4524498
doi: 10.1016/j.parkreldis.2015.04.002
Forsaa, E. B., Larsen, J. P., Wentzel‐Larsen, T., Herlofson, K. & Alves, G. Predictors and course of health-related quality of life in Parkinson’s disease. Mov. Disord. 23, 1420–1427 (2008).
pubmed: 18512757
doi: 10.1002/mds.22121
Burn, D. J. et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 77, 585–589 (2006).
pubmed: 16614017
pmcid: 2117449
doi: 10.1136/jnnp.2005.081711
Arie, L., Herman, T., Shema-Shiratzky, S., Giladi, N. & Hausdorff, J. M. Do cognition and other non-motor symptoms decline similarly among patients with Parkinson’s disease motor subtypes? Findings from a 5-year prospective study. J. Neurol. 264, 2149 (2017).
pubmed: 28879438
doi: 10.1007/s00415-017-8605-x
Amboni, M., Barone, P. & Hausdorff, J. M. Cognitive contributions to gait and falls: evidence and implications. Mov. Disord. 28, 1520–1533 (2013).
pubmed: 24132840
pmcid: 4119872
doi: 10.1002/mds.25674
Woollacott, M. & Shumway-Cook, A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 16, 1–14 (2002).
pubmed: 12127181
doi: 10.1016/S0966-6362(01)00156-4
Allcock, L. M. et al. Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat. Disord. 15, 110–115 (2009).
pubmed: 18487069
doi: 10.1016/j.parkreldis.2008.03.010
Mak, M. K., Wong, A. & Pang, M. Y. Impaired executive function can predict recurrent falls in Parkinson’s disease. Arch. Phys. Med. Rehabil. 95, 2390–2395 (2014).
pubmed: 25175162
doi: 10.1016/j.apmr.2014.08.006
Amar, K., Stack, E., Fitton, C., Ashburn, A. & Roberts, H. C. Fall frequency, predicting falls and participating in falls research: similarities among people with Parkinson’s disease with and without cognitive impairment. Parkinsonism Relat. Disord. 21, 55–60 (2015).
pubmed: 25466401
doi: 10.1016/j.parkreldis.2014.11.001
Srikanth, V. et al. Cerebral white matter lesions, gait, and the risk of incident falls. Stroke 40, 175–180 (2009).
pubmed: 18927448
doi: 10.1161/STROKEAHA.108.524355
Verghese, J. et al. Epidemiology of gait disorders in community-residing older adults. J. Am. Geriatr. Soc. 54, 255–261 (2006).
pubmed: 16460376
pmcid: 1403740
doi: 10.1111/j.1532-5415.2005.00580.x
Aleksovski, D., Miljkovic, D., Bravi, D. & Antonini, A. Disease progression in Parkinson subtypes: the PPMI dataset. Neurol. Sci. 39, 1971–1976 (2018).
pubmed: 30109466
doi: 10.1007/s10072-018-3522-z
Haaxma, C. A. et al. Gender differences in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 78, 819–824 (2007).
pubmed: 17098842
doi: 10.1136/jnnp.2006.103788
Taylor, J.-P. et al. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J. Neurol. Neurosurg. Psychiatry 79, 1318–1323 (2008).
pubmed: 18586866
doi: 10.1136/jnnp.2008.147629
Nutt, J. G. Motor subtype in Parkinson’s disease: different disorders or different stages of disease? Mov. Disord. 31, 957–961 (2016).
pubmed: 27226220
doi: 10.1002/mds.26657
Braak, H., Rüb, U., Gai, W. P. & Del Tredici, K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517–536 (2003).
pubmed: 12721813
doi: 10.1007/s00702-002-0808-2
Meireles, J. & Massano, J. Cognitive impairment and dementia in Parkinson’s disease: clinical features, diagnosis, and management. Front. Neurol. 3, 88 (2012).
pubmed: 22654785
pmcid: 3360424
doi: 10.3389/fneur.2012.00088
Breen, D. P., Michell, A. W. & Barker, R. A. Parkinson’s disease—the continuing search for biomarkers. Clin. Chem. Lab. Med. 49, 393–401 (2011).
pubmed: 21288170
doi: 10.1515/CCLM.2011.080
Skorvanek, M. et al. Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration. Mov. Disord. Clin. Pract. 4, 536–544 (2017).
pubmed: 30363418
pmcid: 6174385
doi: 10.1002/mdc3.12476
Noyce, A. J., Lees, A. J. & Schrag, A.-E. The prediagnostic phase of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 87, 871–878 (2016).
pubmed: 26848171
doi: 10.1136/jnnp-2015-311890
Clarke, C. E. A “cure” for Parkinson’s disease: can neuroprotection be proven with current trial designs? Mov. Disord. 19, 491–498 (2004).
pubmed: 15133811
doi: 10.1002/mds.20057
McGhee, D. J. M., Ritchie, C. W., Zajicek, J. P. & Counsell, C. E. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease. BMC Neurol. 16, 92 (2016).
pubmed: 27312378
pmcid: 4910262
doi: 10.1186/s12883-016-0606-3
van der Heeden, J. F. et al. Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology 86, 2243–2250 (2016).
pubmed: 27178702
doi: 10.1212/WNL.0000000000002768
Ba, F., Obaid, M., Wieler, M., Camicioli, R. & Martin, W. R. W. Parkinson disease: the relationship between non-motor symptoms and motor phenotype. Can. J. Neurol. Sci. 43, 261–267 (2016).
pubmed: 26949837
doi: 10.1017/cjn.2015.328
Eggers, C. et al. Parkinson subtypes progress differently in clinical course and imaging pattern. PLoS ONE 7, e46813 (2012).
pubmed: 23056463
pmcid: 3466171
doi: 10.1371/journal.pone.0046813
Johnson, A. R. et al. Motor subtype as a predictor of future working memory performance in idiopathic Parkinson’s disease. PLoS ONE 11, e0152534 (2016).
pubmed: 27015637
pmcid: 4807780
doi: 10.1371/journal.pone.0152534
Lewis, S. J. G. et al. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J. Neurol. Neurosurg. Psychiatry 76, 343–348 (2005).
pubmed: 15716523
pmcid: 1739569
doi: 10.1136/jnnp.2003.033530
Louis, E. D. et al. Progression of Parkinsonian signs in Parkinson disease. Arch. Neurol. 56, 334–337 (1999).
pubmed: 10190824
doi: 10.1001/archneur.56.3.334
Rajput, A. H., Voll, A., Rajput, M. L., Robinson, C. A. & Rajput, A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73, 206–212 (2009).
pubmed: 19620608
doi: 10.1212/WNL.0b013e3181ae7af1
Rossi, C. et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur. J. Neurol. 17, 626–630 (2010).
pubmed: 20050904
doi: 10.1111/j.1468-1331.2009.02898.x
Zeighami, Y. et al. Assessment of a prognostic MRI biomarker in early de novo Parkinson’s disease. NeuroImage Clin. 24, 101986 (2019).
pubmed: 31514113
pmcid: 6742805
doi: 10.1016/j.nicl.2019.101986
Lee, J. W., Song, Y. S., Kim, H., Ku, B. D. & Lee, W. W. Alteration of tremor dominant and postural instability gait difficulty subtypes during the progression of Parkinson’s disease: analysis of the PPMI Cohort. Front. Neurol. 10, 471 (2019).
pubmed: 31133973
pmcid: 6514149
doi: 10.3389/fneur.2019.00471
D’Souza, T. & Rajkumar, A. P. Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson’s disease. Acta Neuropsychiatr. 32, 10–22 (2020).
pubmed: 31292011
doi: 10.1017/neu.2019.28
Kozlovski, T. et al. Hierarchical data-driven analysis of clinical symptoms among patients with Parkinson’s disease. Front. Neurol. 10, 531 (2019).
pubmed: 31164863
pmcid: 6536639
doi: 10.3389/fneur.2019.00531
Harrison, M. B. et al. UPDRS activity of daily living score as a marker of Parkinson’s disease progression. Mov. Disord. 24, 224–230 (2009).
pubmed: 18951537
pmcid: 3103833
doi: 10.1002/mds.22335
Lord, S. et al. Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson’s disease. Front. Aging Neurosci 6, 249 (2014).
pubmed: 25374538
pmcid: 4205301
doi: 10.3389/fnagi.2014.00249
Barter, J. W., Castro, S., Sukharnikova, T., Rossi, M. A. & Yin, H. H. The role of the substantia nigra in posture control. Eur. J. Neurosci. 39, 1465–1473 (2014).
pubmed: 24628921
doi: 10.1111/ejn.12540
Takakusaki, K. Functional neuroanatomy for posture and gait control. J. Mov. Disord. 10, 1–17 (2017).
pubmed: 28122432
pmcid: 5288669
doi: 10.14802/jmd.16062
Martín-Gallego, A. et al. Brainstem and autonomic nervous system dysfunction: a neurosurgical point of view. Acta Neurochir. Suppl. 124, 221 (2017).
pubmed: 28120078
doi: 10.1007/978-3-319-39546-3_34
Braak, H. et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J. Neurol. 249, III/1–III/1 (2002).
doi: 10.1007/s00415-002-1301-4
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 318, 121 (2004).
pubmed: 15338272
doi: 10.1007/s00441-004-0956-9
Blauwendraat, C., Bandrés-Ciga, S. & Singleton, A. B. Predicting progression in patients with Parkinson’s disease. Lancet Neurol. 16, 860–862 (2017).
pubmed: 28958800
pmcid: 6005700
doi: 10.1016/S1474-4422(17)30331-9
Erro, R. et al. The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS ONE 8, e70244 (2013).
pubmed: 23936396
pmcid: 3731357
doi: 10.1371/journal.pone.0070244
Greenland, J. C., Williams-Gray, C. H. & Barker, R. A. Clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur. J. Neurosci. https://doi.org/10.17863/CAM.30385 (2018).
Sato, K. et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov. Disord. 21, 1384–1395 (2006).
pubmed: 16763980
doi: 10.1002/mds.20993
Birkmayer, W., Riederer, P. & Youdim, M. B. H. Distinction between benign and malignant type of parkinson’s disease. Clin. Neurol. Neurosurg. 81, 158–164 (1979).
pubmed: 230930
doi: 10.1016/0303-8467(79)90003-9
Espay, A. J. et al. Biomarker‐driven phenotyping in Parkinson’s disease: a translational missing link in disease‐modifying clinical trials. Mov. Disord. 32, 319–324 (2017).
pubmed: 28233927
pmcid: 5359057
doi: 10.1002/mds.26913
Marek, K. et al. The Parkinson progression marker initiative (PPMI). Prog. Neurobiol. 95, 629–635 (2011).
doi: 10.1016/j.pneurobio.2011.09.005